Fortis Capital Management LLC Takes Position in Boston Scientific Corporation $BSX

Fortis Capital Management LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 60,382 shares of the medical equipment provider’s stock, valued at approximately $5,895,000.

A number of other large investors have also bought and sold shares of BSX. Riverwater Partners LLC grew its holdings in shares of Boston Scientific by 3.3% in the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management raised its holdings in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 99 shares during the last quarter. Crown Wealth Group LLC boosted its position in Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after buying an additional 100 shares during the period. Sound View Wealth Advisors Group LLC grew its holdings in Boston Scientific by 3.9% in the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 103 shares during the last quarter. Finally, Scotia Capital Inc. increased its position in shares of Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after acquiring an additional 104 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 1.6%

Shares of NYSE BSX opened at $74.54 on Monday. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a 50-day moving average of $89.23 and a 200 day moving average of $96.53. The stock has a market cap of $110.61 billion, a P/E ratio of 38.42, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business earned $0.70 earnings per share. The business’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BSX shares. Mizuho dropped their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Citigroup decreased their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Morgan Stanley cut their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Finally, Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $108.36.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.